Inspire Medical Systems (INSP)

What Moves the Stock

1. 01Quarterly procedure volume growth rates and guidance - market expects 15-20% annual growth through 2028
2. 02Medicare and commercial reimbursement policy changes, particularly CMS coverage decisions and prior authorization requirements
3. 03Competitive threats from pharmaceutical weight loss therapies (GLP-1 agonists) potentially reducing OSA patient population
4. 04New clinical data supporting label expansions (pediatric indication, mild OSA, complete concentric collapse patients)
5. 05International market penetration rates, particularly Germany reimbursement and Japan regulatory approval timeline
6. 06Inspire therapy system sales (implantable pulse generator, sensing lead, stimulation lead) representing ~95% of revenue
7. 07International sales primarily in Germany and other European markets representing ~5-10% of revenue
8. 08Recurring revenue from device replacements (battery life ~11 years) creating long-term annuity stream

INSP Chart

My Notes

• growth - Stock historically traded at premium valuations (40-50x forward earnings pre-correction) attracting growth investors focused…
• Rising rates create modest headwind through two channels: (1) higher discount rates compress valuation multiples for high-growth medtech…
• Watch on earnings: Quarterly US procedure volumes and sequential growth trends vs. historical 15-20% CAGR, Medicare reimbursement rates and coverage policy updates from CMS, Active implanting physician count and quarterly new surgeon additions.